NCT06084299

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (estimated)
• Sponsor: Zhiyong Huang · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Single-arm, open-label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TIL) infusion followed by IL-2 after a non-myeloablative(NMA) lymphodepletion preparative regimen for the treatment of patients with advanced liver cancer.

Detailed description

This is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process for the treatment of patients with advanced liver cancer. The cell transfer therapy used in this study involves patients receiving a non-myeloablative lymphodepletion preparative regimen, followed by i.v. infusion of autologous tumor-infiltrating lymphocytes followed by the administration of a regimen of IL-2.

Conditions

• Liver Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Autologous Tumor Infiltrating Lymphocytes	Fresh tumor samples will be resected from enrolled patients. Autologous TILs will be extracted and reinfused to corresponding patients after ex vivo stimulation, activation, and extensive expansion.

Timeline

• Start date: 2020-05-27
• Primary completion: 2026-08-30
• Completion: 2026-08-30
• First posted: 2023-10-16
• Last updated: 2025-08-19

Locations

1 site across 1 country: China